Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listNateglinide

Nateglinide

Synonym(s):Fastic;N-[(trans-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine;Starlix;Starsis

  • CAS NO.:105816-04-4
  • Empirical Formula: C19H27NO3
  • Molecular Weight: 317.42
  • MDL number: MFCD00875706
  • EINECS: 641-756-7
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-19 15:53:33
Nateglinide Structural

What is Nateglinide?

Absorption

Rapidly absorbed following oral administration prior to a meal, absolute bioavailability is estimated to be approximately 73%. Peak plasma concentrations generally occur within 1 hour of oral administration. Onset of action is <20 minutes and the duration of action is approximately 4 hours.

Toxicity

An overdose may result in an exaggerated glucose-lowering effect with the development of hypoglycemic symptoms.

Description

Nateglinide is a N-acylated D-phenylalanine marketed in Japan as novel orally active insulinotropic agent for the treatment of type-2 diabetes mellitus. It belongs to the class of nonsulfonylureas and shows some structural similarity to repaglinide, the only other representative in this family. In single pancreatic beta-cells isolated from rats, Nateglinide was found to specifically block the ATP-sensitive K+ channel resulting in an increase in intracellular calcium concentration. This primary action would underlie the mechanism by which Nateglinide markedly stimulates or potentiates, depending on glucose concentrations, insulin secretion from pancreatic beta-cells. Clinical studies demonstrated a good safety profile with a low potential for hypoglycemia. The pharmacokinetic profile was consistent with the changes of the blood glucose and plasma insulin level. Interestingly, Nateglinide exerts a rapid onset and short duration of action due to a rapid absorption and clearance. Unlike other similar agents, Nateglinide suppresses postprandial glucose elevations.

Chemical properties

Cyrstalline Solid

Originator

Ajinomoto (Japan)

The Uses of Nateglinide

An Amino-acid derivative that stimulates insulin secretion. Used as an antidiabetic

The Uses of Nateglinide

antidiabetic KATP channel blocker

The Uses of Nateglinide

An amino-acid derivative that stimulates insulin secretion. Used as an antidiabetic.

Indications

For the treatment of non-insulin dependent-diabetes mellitus in conjunction with diet and exercise.

Background

Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those na?ve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound.

What are the applications of Application

Nateglinide is an amino-acid derivative that stimulates insulin secretion

Definition

ChEBI: An N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-ad inistered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus.

brand name

Starlix (Novartis);Fastic;Starsis.

General Description

Although nateglinide, N-(4-isopropylcyclohexanecarbonyl)-D-phenylalanine (Starlix), belongs tothe metaglinides, it is a phenylalanine derivative and representsa novel drug in the management of type 2 diabetes.

General Description

Nateglinide (Starlix) is D-Phenylalanine, N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-; or (-)-N-[(trans-4-isopropylcyclohexyl)carbonyl]-D-phenylalanine. Itis noteworthy that, although nateglinide is much less potenton a dosage basis than is repaglinide and most of the sulfonylureas,this drug seems to exhibit unique molecularpharmacodynamics. Nateglinide closes ATP-sensitive K channels some threefold more rapidly than repaglinide, andexhibits an off-rate twice as fast as that of glyburide orglimepiride and five times faster than repaglinide. Thesecharacteristics are reflected by the systemic pharmacodynamicsof this drug, translating clinically to improvedsafety, among other apparent benefits.

Biochem/physiol Actions

Nateglinide is a Kir6.2/SUR1 channel inhibitor and antidiabetic. It is selective for the SUR1 subtype, which is found on pancreatic islet cells. Nateglinide evokes KATP channel-dependent insulin secretion (50-200 μM) in the absence and presence of insulin.

Mechanism of action

Approved in the United States in late 2000, nateglinide is a rapidly absorbed insulin secretagogue that has a mechanism of action similar to that of repaglinide, with effects appearing within 20 minutes following oral dosing. Bioavailability is 73%, and it is 98% protein bound, primarily to albumin. Nateglinide is tissue selective, with low affinity for cardiac and skeletal muscle.

Pharmacokinetics

Insulin secretion by pancreatic β cells is partly controlled by cellular membrane potential. Membrane potential is regulated through an inverse relationship between the activity of cell membrane ATP-sensitive potassium channels (ABCC8) and extracellular glucose concentrations. Extracellular glucose enters the cell via GLUT2 (SLC2A2) transporters. Once inside the cell, glucose is metabolized to produce ATP. High concentrations of ATP inhibit ATP-sensitive potassium channels causing membrane depolarization. When extracellular glucose concentrations are low, ATP-sensitive potassium channels open causing membrane repolarization. High glucose concentrations cause ATP-sensitive potassium channels to close resulting in membrane depolarization and opening of L-type calcium channels. The influx of calcium ions stimulates calcium-dependent exocytosis of insulin granules. Nateglinide increases insulin release by inhibiting ATP-sensitive potassium channels in a glucose-dependent manner.

Clinical Use

Treatment of type 2 diabetes in combination with metformin

Drug interactions

Potentially hazardous interactions with other drugs
Antibacterials: concentration reduced by rifampicin.
Antifungals: hypoglycaemic effect possibly enhanced by fluconazole.
Lipid-lowering agents: hypoglycaemic effect possibly enhanced by gemfibrozil.

Metabolism

Hepatic, via cytochrome P450 isoenzymes CYP2C9 (70%) and CYP3A4 (30%). Metabolism is via hydroxylation followed by glucuronidation. The major metabolites have less antidiabetic activity than nateglinide, but the isoprene minor metabolite has antidiabetic activity comparable to that of nateglinide.

Metabolism

It is metabolized in the liver, with 16% excreted in the urine unchanged. The major metabolites are hydroxyl derivatives (CYP2C9, 70%; CYP3A4, 30%) that are further conjugated to the glucuronide derivatives.

storage

Store at RT

Properties of Nateglinide

Melting point: 137-141°C
Boiling point: 527.6±39.0 °C(Predicted)
alpha  D20 -9.4° (c = 1 in methanol)
Density  1.104±0.06 g/cm3(Predicted)
storage temp.  room temp
solubility  DMSO: >5mg/mL
form  solid
pka 3.61±0.10(Predicted)
color  white to off-white
Merck  14,6428
CAS DataBase Reference 105816-04-4(CAS DataBase Reference)

Safety information for Nateglinide

Computed Descriptors for Nateglinide

Abamectin manufacturer

KARPSCHEM LABORATORIES PVT. LTD.

1Y
Phone:+917249203006
Whatsapp: +91 7249203006
product: 105816-04-4 96%
Inquiry

Cipla Ltd

1Y
Phone:+912224826000
product: Nateglinide 98%
Inquiry

Hetero Drugs Limited

1Y
Phone:+914023704923
product: Nateglinide 105816-04-4 98%
Inquiry

Unichem Laboratories Ltd

1Y
Phone:+91-2266888333
product: 105816-04-4 Nateglinide 98%
Inquiry

Dayaram Pharma Chem

1Y
Phone:+91-9601766800
Whatsapp: +91 9601766800
product: 105816-04-4 98%
Inquiry

Ralington Pharma

1Y
Phone:+91-9687771722
Whatsapp: +91- 9687771722
product: Nateglinide 98%
Inquiry

Ind Swift Laboratories Ltd

1Y
Phone:+91-1126226140
product: Nateglinide 105816-04-4 99%
Inquiry

Niksan Pharmaceutical

1Y
Phone:+91-9537871777
Whatsapp: +91-9537871777
product: 105816-04-4 99%
Inquiry

Cipla Ltd.

Maharashtra
product: Nateglinide
Inquiry

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.